- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04206891
CDH1 Germline Mutations in Lobular Breast Cancer
Understanding How CDH1 Germline Mutations Affect Hereditary Lobular Breast Cancer
Invasive lobular breast carcinoma (ILBC) represents 5-15% of all invasive BCs. The CDH1 gene (OMIM no. 192090), located on the chromosome 16q22.1, encodes for the E-cadherin protein, a key regulator of cell adhesion. Loss of E-cadherin expression is frequently detected in LBC CDH1 germline loss-of-function mutations are associated with the autosomal dominant cancer-predisposition syndrome, hereditary diffuse gastric cancer (HDGC; OMIM no. 137215). The cumulative risk of LBC for women with a CDH1 mutation is estimated to be 42% (95% CI 23% to 68%) by 80 years, when it is a component of HDGC syndrome.
Recently, some authors described CDH1 germline mutations in women with in situ or ILBC with early onset (<45 or <50) and bilateral in situ or ILBC with no family history of HDGC. These results are opening a new scenario, suggesting that CDH1 could be a susceptibility gene for LBC in women without a family history of DGC.
The first aim of this study is to investigate prevalence of CDH1 in this specific population of women with early onset (<45 or <50) in situ or ILBC, bilateral LBC or LBC with no family history of HDGC.
Study Overview
Status
Conditions
Detailed Description
Invasive lobular breast carcinoma (ILBC) represents 5-15% of all invasive BCs. LBC presents relevant differences in the transcriptomic profiles, metastatic pattern, and clinical behaviour compared to infiltrating ductal BC.
The CDH1 gene (OMIM no. 192090), located on the chromosome 16q22.1, encodes for the E-cadherin protein, a key regulator of cell adhesion. Loss of E-cadherin expression is frequently detected in LBC.
CDH1 germline loss-of-function mutations are associated with the autosomal dominant cancer-predisposition syndrome, hereditary diffuse gastric cancer (HDGC; OMIM no. 137215). The cumulative risk of LBC for women with a CDH1 mutation is estimated to be 42% (95% CI 23% to 68%) by 80 years, when it is a component of HDGC syndrome.
Recently, updated clinical guidelines for CDH1 testing criteria have been published. For LBC, CDH1 genetic screening has been suggested for families with diagnosed of both DGC and LBC (one diagnosis before the age of 50) and patients with bilateral or familial LBC before the age of 50.
Recently, some authors described CDH1 germline mutations in women with in situ or ILBC with early onset (<45 or <50) and bilateral in situ or ILBC with no family history of HDGC. These results are opening a new scenario, suggesting that CDH1 could be a susceptibility gene for LBC in women without a family history of DGC.
The investigators have revised all literature data about early-onset LBC and CDH1 germline mutations, excluding pedigrees associated with DGCs. In detail, 482 cases of LBCs were screened for CDH1 constitutional mutations. Family history for breast carcinoma was documented in 40.7 % of the considered probands and 20.3 % presented a bilateral BC manifestation. Mean age at onset was 46 years. Fourteen novels deleterious alterations (2.9 %) have been reported; 5 were missense (35.7 %), 3 mutations affected the splicing sites (21.4 %), 3 deletions (21.4 %), 2 insertions (14.3 %) and 1 stop codon (7.2 %). These mutations affect different CDH1 gene domains, spanning almost all 16 exons and introns 1-7-13 boundaries. Two missense mutations were defined as potentially pathogenic variants in vitro and in silico analysis [Corso et al. Fam Cancer 2016]. Overall, about 3% of the screened population with LBC have a mutation.
To date, no clear-cut genetic indicators for increased risk have been identified in patients with lobular breast cancer (LBC).
The first aim of this study is to investigate prevalence of CDH1 in this specific population of women with early onset (<45 or <50) in situ or ILBC, bilateral LBC or LBC with no family history of HDGC.
The investigators hypothesize that CDH1 is a susceptibility gene for LBC and that a novel and rare syndrome (called as hereditary LBC), independent from the classic HDGC setting, should be described, especially in subjects with early onset of LBC, before 45 years at diagnosis, and in bilateral LBC manifestation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Milan, Italy
- European Institute of Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
From 1997 to 2016 we collected data from a total of 1544 patients with invasive LBC and 230 with in situ histotype.
For CDH1 genetic screening, an additional population will be considered prospectively between the range 2017-2018 Among them we will have to identified patients with a BRCA1/2 pathogenetic mutation.
Description
Inclusion Criteria:
- Bilateral lobular breast cancer or Lobular breast cancer with age at onset <= 45 years or Lobular breast cancer with family history for breast cancer
- Patients with blood available in IEO biobank
Exclusion Criteria:
- Patients with a previous cancer (except for colon cancer, stomach cancer and lobular breast cancer).
- Patients with germline BRCA1/2 patogenetic mutation will be excluded
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
---|
Group 1
Bilateral lobular invasive breast cancer
|
Group 2
Invasive lobular breast cancer with age at onset <= 45 years
|
Group 3
Invasive lobular breast cancer with family history for breast cancer
|
Group 4
In situ lobular breast cancer with age at onset <= 45 years
|
Group 5
In situ lobular breast cancer with family history for breast cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative frequency of patients with a mutation in CDH1 germline
Time Frame: 6 months
|
Number of patients with mutation in CDH1 germline per each group identified
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of patients with a mutation in CDH1 germline by disease status
Time Frame: 6 months
|
Number of patients with a mutation in CDH1 germline stratified by disease status to investigate the prevalence of this mutation status between invasive and in situ BC
|
6 months
|
Frequency of patients with a mutation in CDH1 germline by clinical strata
Time Frame: 6 months
|
Number of patients with a mutation in CDH1 germline stratified by clinical data to investigate the prevalence of this mutation status betweenr early onset LBC (<45 years), bilateral LBC and LBC with family history for breast cancer
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Giovanni Corso, MD, European Institute of Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IEO 0834/
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lobular Breast Carcinoma
-
Auxilio Mutuo Cancer CenterUnknownInfiltrating Duct and Lobular Carcinoma In Situ | Invasive Lobular Breast Carcinoma | Inflammatory Breast CarcinomaPuerto Rico
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
Istituto Oncologico Veneto IRCCSRecruitingPleomorphic Lobular Breast Carcinoma in Situ | Breast Florid Lobular Carcinoma in SituItaly
-
Amy C. DegnimNational Cancer Institute (NCI)RecruitingBreast Atypical Lobular Hyperplasia | Breast Atypical Hyperplasia | Breast Lobular Carcinoma in SituUnited States
-
University of UtahRecruitingInvasive Lobular Breast CarcinomaUnited States
-
Mayo ClinicRecruitingBreast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Lobular Carcinoma In SituUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedBreast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Invasive Breast CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Lobular Carcinoma | Metastatic Breast Lobular CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States